Dr. Mitchell Steiner
provide Thank are Steiner, our of Development joining Corporate financial Senior our we on Today, President will development XXXX. the first of for President, update highlights and as And clinical well is drug Legal. Veru the of and commercialization Inc. you, and me Dr. Mitchell provide Vice pipeline; an morning. and Greco, and products, Kevin as CEO CFO fiscal quarter CAO; Gilbert, operator, Michele This good
transitions good to oncology Veru urology progress company. making as We are a biopharmaceutical and
file in and to the we several time multiple drugs oncology. clinical at under revenue near-term same and urology Our mid-term in commercial is that development ensure growth have several NDAs strategy and near-term drugs for to progressing the
NDAs drugs. months, to file for Over the we expect next four XX three
two DRS, branded in slow release These First, we Tamsulosin and Tamsulosin drug Tamsulosin formulations. FLOMAX important in are clinical for formulation granule two found formulations current release that challenges the XR two granules oral capsules. products, and new address drug proprietary suspension extended of have generic new
FLOMAX appear dollar multi-billion men compliance, when not will broader minutes XR blood we release and have drug XX actually conducted. capsule to in proprietary XR markets offer Because resulting gets capsules granules capsules granule men according as of Tamsulosin swallow XX% cannot care in amount meaning capsule it in community has only who a may does instructed for may effect, levels new or greater clinical after slow must stomach, XX% plan form. including as Tamsulosin form, of insert, release the of package and to primary low capsules. and the BPH FLOMAX take care that us new or drug not to this formulation, is given studies effect, urology expand slow effects in should the crushed, serious food be a cannot long-term given capsules. is of it pressure to can tables FLOMAX granule available release administration blood chewed And who The First, those FLOMAX, have challenge A higher dizziness. side to absorbed, based allow because on the formulation slow be a FDA. a and in DRS, pills food be and lead men an empty these or to advantage drug to FDA The by Tamsulosin meal. bioequivalent rapidly given difficulty and swallow the with have second Tamsulosin a of on that opened, we
prostatic urination, X.X suspension extended BPH. prostrate an symptoms in for hyperplasia Tamsulosin of filling We the and clinical data This for of expect final enlarged planned bioequivalence XR known milligram is NDA causing XXXX HCL release benign as milligrams, for launch in an Tamsulosin X.X the which and difficulty XXXX. or capsules, DRS is oral treatment Tamsulosin also
difficulties ingredient that Solifenacin proprietary granular antagonists a instructed Our of urge a for drug release Solifenacin treatment incontinence muscarinic swallowed are and granule the be states tablets active Similarly, swallow the in Solifenacin, urology formulation this FLOMAX, is of bladder bladder, for common both whole. formulations women. women is or no overactive men class condition called package selective and the the class tablets. popular delayed VESIcare, MX frequency who for of or the drug have There as urgency, overactive of in drugs, and who must FDA receptor available DRG is which second have for cannot the for insert
the complete DRG of or Health proprietary release Prevalence overactive a granule bladder XX% age. Human women of of recent between did as Department be slow market XX% have the The and Resources, XX% is long-term will overactive long-term formulation. difficulty bladder to bladder technology cannot facilities a and same population target our United the also and platform Consequently, delivery opportunity. bladder multi-billion Our who and men study with formulation swallow by utilizes the States tablets. in with control. residents symptoms According increases Solifenacin conducted initial Tamsulosin DRS not of care nursing home and have in short-term XX% is overactive
be place to DRS. already expect utilize same channels We for the in sales would that Tamsulosin
NDA data granules in bioequivalence filling clinical slow Solifenacin men release the treatment and XXXX. for bladder DRG, XXXX expect and overactive in women in an We final for a
which milligrams, capsule Proscar, shrinking have third offer BPH which dysfunction that formulation, active in allow Tadalafil drug Our formulation signs will approved is a portfolio of is X the to and to for combination combination mechanisms of X urology and different approved drugs which the contains a formulation Tadalafil/Finasteride Tadalafil prostate treat The this us BPH. X Finasteride treat CIALIS, of milligrams enlarged capsule BPH. of proprietary milligrams, milligrams proprietary to the different treatment symptoms ingredients for actually X is erectile combination Finasteride and is new BPH
while smaller formulation the shrinks combination of final men prevents capsule size and the XXXX in an prostate in clinical who prostate, enlarged quickly the whereas anticipate lower an with symptoms present treats Tadalafil/Finasteride For bioequivalence capsule data example, the in of Tadalafil/Finasteride symptoms because also with of and treats growth combination quickly of of for the formulation urinary Tamsulosin it BPH, have progressive men NDA BPH We actually prostate, enlarged filing symptoms in a treatment an urinary XXXX. urinary prostate.
combination years. prostate and capsules; VERU-XXX, include These to which over treatment the the on clinical appropriate, agreed urology citrate study. cis-clomiphene urology pharmaceuticals We the overactive X as therapy dollar will opportunities. multi-billion advantage oncology half multiple The are XXXX, well-positioned the DRG and May of and take of DRS bladder us hot granules, well men wave products, In of to NDAs, granules, Tamsulosin Solifenacin partner BPH file two will of Tadalafil/Finasteride dose-finding Tamsulosin allow when and to drugs in is a cancer. as may advanced capsules four Phase and launch FDA are that XR next VERU-XXX advance treat hormone who for into flashes next
We patent in issued the will expected with XXXX. in Phase clinical early IND U.S. the be was X and It that VERU-XXX XXXX in trial the the early will recently should noted for initiate expire and file XXXX. clinical data
that targets of the developing also anti-tubulin other for alpha prostate, & treatment subunits advanced ovarian, metastatic oral of novel breast, and We’re microtubules VERU-XXX, therapy beta tubulin endometrial a cancers.
the and clinical trials studies the be completing half preclinical begin ready second the will to by XXXX. are We of required
part metastatic clinical men latter see the who therapies data cancer We the clinical Phase hormonal men target label drugs clinical in metastatic will or X/X In that Phase trials cancer portion who will failed annual will in break is initially in the who to today dollars are include with prostate prostate through. which ZYTIGA, means current have in the with we These the which of X we are castration-resistant of enzalutamide. a have unfortunately study, open trial, is start generating abiraterone, several hormone failed, will and [ph] revenue become resistant cancer men to, have castration-resistant prostate which billion XTANDI, XXXX.
Oncology $X In annual VERU-XXX chemotherapies, types therapy Scientific oral of is was are developed for an treated data at in presentations March presented XXXX. today. at in Copenhagen, be American opportunity, recently by well for over currently that XXXX of Association large meetings being of in Urology billion GU the accepted in and Denmark, been of addition, given Clinical American can a Association intravenously and has other Society the European revenues Urologic for future also May in of Francisco, VERU-XXX Francisco anti-tubulin market the meeting which San as pre-clinical tumor San
internally have drugs. full urology pharmaceutical advancing pipeline opportunistic to license and/or also We both developing by new finding products continue in oncology. and and of to be We’ll a
governments FCX debt or FCX the in customers, from global world’s With beat XXXX the a South our need public more units. better our sector, aggressively this the in business our Africa tender these female unit global and our The felt quarter to as year from female protect lot we division Health our their channel the three not regulatory is public division competition commercial health Brazil condom a totaling both financing. than by and quantities year year XXX clinical of activities the paid years, awarding of place Female and do Health resources We impact this the accomplished due expected two XX award drugs. the PREBOOST. normal to Africa, leading year by by and agencies first produced past our In is of Female million the health revenue with believe is brand, now We sector and pipeline health and U.S. public did year to growing have The global a of XX development non-governmental be orders advancing without part ever, undertaking in South has Company Brazil for separate should donor million market. distribution. the where for FCX products, and and from bulk per this clarity for tender procurement grow revenue purchased who the revenues million fiscal Company this is to international existing obtaining condom. competition, We cycles. able product were sector, year our public unit This this for a equity largest We
pregnancies we beyond. and FCX orders virus. Zika that prevent of XXXX, including positioned both is condom some from market, XXXX to In U.S. get these both unwanted STIs, will tenders the uniquely the the confident HIV/AIDS as and transmission and sexual female of FDA-approved We’re one in only of
service was distribution and challenge the to market. marketing Our create to U.S.
across areas last private we’re new with is Act I seeing prescription a new and by the under FCX pharmacies Act. month, in the reimbursable revenue laws have We under place, Care reimbursement public of payers traction reported infrastructure and the access of Affordable these the market of so market in and now both prior distribution, available access. country. to numerous over Affordable As with reimbursable XX% pharmacy states retail and in is Care the FCX
small We market have care people a sales about to OB-GYN XX physicians. force that primary of and
the we eliminated health organizations margins. of and middlemen directly sell have departments will now to with We distributors and better FCX community
agreement as HIV covered is have service a directly We to and STD signed to such approximately entities, master which entities XXXb XX,XXX sell clinics.
application, app where be the could We with the FCX Apple, pharmacy. home have via specialty ship to local obtained patient the their smartphone a partnered an telemedicine prescription so by could be prescription to that this an Android sent by pharmacy an or their HeyDoctor via
a grow. and assistance active program, finally, where that an to purchase can from colleges And the FCX We our underinsured universities continues an website. at program or have have individual we uninsured discount
with the were seasoned to of contracted being market. hybrid possibility to FCX for are FCX the and year. I and this our sales efforts we’re and X,XXX marketing million independent past efforts months, average expand OB-GYN new seeing pleased independent who and U.S. force of past revenues months, in we’re near-term exploring report of four established XX the been marketing in contractors U.S. relationships care people years three four these of the for revenues million. sales annual selling growing in have past $X.X the As a U.S. I’m revenue new $X.X the offices. to a in people progress, over mentioned, to the in the primary because Because finally just the up Historically, about generated the
no FCX commission compensated this alone. a additional As incur is sales Company will on sales ramp people expenses. number up to be contracted this force, The sales by should of our
discuss to and the we the Our ejaculation. other digital social financial launched Technologies, I into to for We CFO, agreement a PREBOOST with benzocaine prevention wipes opportunity organization. X% and will Timm a of over marketing entered Greco, revenue Medical specialty of distribution highlights. turn call PREBOOST, via Michele urology premature now media sales the is also co-promotion Michele?
